290 related articles for article (PubMed ID: 33183957)
1. Cytokines in oncolytic virotherapy.
Pol JG; Workenhe ST; Konda P; Gujar S; Kroemer G
Cytokine Growth Factor Rev; 2020 Dec; 56():4-27. PubMed ID: 33183957
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic Virotherapy and the Tumor Microenvironment.
Berkey SE; Thorne SH; Bartlett DL
Adv Exp Med Biol; 2017; 1036():157-172. PubMed ID: 29275471
[TBL] [Abstract][Full Text] [Related]
3. Arming oncolytic viruses to leverage antitumor immunity.
de Gruijl TD; Janssen AB; van Beusechem VW
Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450
[TBL] [Abstract][Full Text] [Related]
4. Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy.
Zhang B; Cheng P
Mol Cancer; 2020 Nov; 19(1):158. PubMed ID: 33172438
[TBL] [Abstract][Full Text] [Related]
5. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
Front Immunol; 2019; 10():1848. PubMed ID: 31440242
[TBL] [Abstract][Full Text] [Related]
6. Molecular Circuits of Immune Sensing and Response to Oncolytic Virotherapy.
Bhatt DK; Daemen T
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731910
[TBL] [Abstract][Full Text] [Related]
7. Multidirectional Strategies for Targeted Delivery of Oncolytic Viruses by Tumor Infiltrating Immune Cells.
Osali A; Zhiani M; Ghaebi M; Meymanat M; Esmaeilzadeh A
Pharmacol Res; 2020 Nov; 161():105094. PubMed ID: 32795509
[TBL] [Abstract][Full Text] [Related]
8. Integrating oncolytic viruses in combination cancer immunotherapy.
Bommareddy PK; Shettigar M; Kaufman HL
Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulation in Oncolytic Measles Virotherapy.
Dietz L; Engeland CE
Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
[TBL] [Abstract][Full Text] [Related]
10. Gene-based delivery of immune-activating cytokines for cancer treatment.
Rossari F; Birocchi F; Naldini L; Coltella N
Trends Mol Med; 2023 Apr; 29(4):329-342. PubMed ID: 36828711
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic Immunotherapy: Can't Start a Fire Without a Spark.
Muscolini M; Tassone E; Hiscott J
Cytokine Growth Factor Rev; 2020 Dec; 56():94-101. PubMed ID: 32826166
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic virotherapy for pancreatic ductal adenocarcinoma: A glimmer of hope after years of disappointment?
Tassone E; Muscolini M; van Montfoort N; Hiscott J
Cytokine Growth Factor Rev; 2020 Dec; 56():141-148. PubMed ID: 32859494
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic T lymphocyte-associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells.
Liu W; Liu Y; Hu C; Xu C; Chen J; Chen Y; Cai J; Yan G; Zhu W
Int J Cancer; 2021 Sep; 149(6):1369-1384. PubMed ID: 34086978
[TBL] [Abstract][Full Text] [Related]
14. The pros and cons of interferons for oncolytic virotherapy.
Geoffroy K; Bourgeois-Daigneault MC
Cytokine Growth Factor Rev; 2020 Dec; 56():49-58. PubMed ID: 32694051
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive characterization of tumor immune landscape following oncolytic virotherapy by single-cell RNA sequencing.
Ravirala D; Pei G; Zhao Z; Zhang X
Cancer Immunol Immunother; 2022 Jun; 71(6):1479-1495. PubMed ID: 34716463
[TBL] [Abstract][Full Text] [Related]
16. The oncolytic virus ΔPK has multimodal anti-tumor activity.
Aurelian L; Bollino D; Colunga A
Pathog Dis; 2016 Jul; 74(5):. PubMed ID: 27242376
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies.
Workenhe ST; Mossman KL
Mol Ther; 2014 Feb; 22(2):251-256. PubMed ID: 24048442
[TBL] [Abstract][Full Text] [Related]
18. Detection of Tumor Antigen-Specific T-Cell Responses After Oncolytic Vaccination.
Pol JG; Bridle BW; Lichty BD
Methods Mol Biol; 2020; 2058():191-211. PubMed ID: 31486039
[TBL] [Abstract][Full Text] [Related]
19. Natural Killer Cells Recruitment in Oncolytic Virotherapy: A Mathematical Model.
Senekal NS; Mahasa KJ; Eladdadi A; de Pillis L; Ouifki R
Bull Math Biol; 2021 May; 83(7):75. PubMed ID: 34008149
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
[No Abstract] [Full Text] [Related]
[Next] [New Search]
